Literature DB >> 30779526

Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.

Bernard Escudier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30779526     DOI： 10.1056/NEJMe1900887

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

Review 1.  Progress in refining the clinical management of cancer of unknown primary in the molecular era.

Authors:  Elie Rassy; Nicholas Pavlidis
Journal:  Nat Rev Clin Oncol       Date:  2020-04-29       Impact factor: 66.675

2.  Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.

Authors:  Koichi Kido; Shingo Hatakeyama; Kazuyuki Numakura; Toshikazu Tanaka; Masaaki Oikawa; Daisuke Noro; Shogo Hosogoe; Shintaro Narita; Takamitsu Inoue; Takahiro Yoneyama; Hiroyuki Ito; Shoji Nishimura; Yasuhiro Hashimoto; Toshiaki Kawaguchi; Tomonori Habuchi; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2020-10-16       Impact factor: 3.402

3.  First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.

Authors:  Shaan Dudani; Jeffrey Graham; J Connor Wells; Ziad Bakouny; Sumanta K Pal; Nazli Dizman; Frede Donskov; Camillo Porta; Guillermo de Velasco; Aaron Hansen; Marco Iafolla; Benoit Beuselinck; Ulka N Vaishampayan; Lori A Wood; Elizabeth Liow; Flora Yan; Takeshi Yuasa; Georg A Bjarnason; Toni K Choueiri; Daniel Y C Heng
Journal:  Eur Urol       Date:  2019-08-22       Impact factor: 20.096

4.  Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.

Authors:  Jun Chen; Gaoyun Hu; Zhuo Chen; Xiaomin Wan; Chongqing Tan; Xiaohui Zeng; Zeneng Cheng
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

5.  Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  Brandon J Manley; Philipp M Altrock; Meghan C Ferrall-Fairbanks; Nicholas H Chakiryan; Boris I Chobrutskiy; Youngchul Kim; Jamie K Teer; Anders Berglund; James J Mulé; Michelle Fournier; Erin M Siegel; Jasreman Dhillon; Seyed Shayan A Falasiri; Juan F Arturo; Esther N Katende; George Blanck
Journal:  Cancer Res       Date:  2022-03-01       Impact factor: 12.701

6.  Associations between tumor grade, contrast-enhanced ultrasound features, and microvascular density in patients with clear cell renal cell carcinoma: a retrospective study.

Authors:  Xia Meng; Ran Yang; Shengnan Zhao; Zhixia Sun; Hui Wang
Journal:  Quant Imaging Med Surg       Date:  2022-03

7.  Real world data on IO-based therapy for metastatic renal cell carcinoma.

Authors:  Viktoria Stühler; Lisa Herrmann; Steffen Rausch; Arnulf Stenzl; Jens Bedke
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-30       Impact factor: 4.322

8.  Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study.

Authors:  Matteo Brunelli; Guido Martignoni; Giorgio Malpeli; Alessandro Volpe; Luca Cima; Maria Rosaria Raspollini; Mattia Barbareschi; Alessandro Tafuri; Giulia Masi; Luisa Barzon; Serena Ammendola; Manuela Villanova; Maria Angela Cerruto; Michele Milella; Sebastiano Buti; Melissa Bersanelli; Giuseppe Fornarini; Sara Elena Rebuzzi; Valerio Gaetano Vellone; Gabriele Gaggero; Giuseppe Procopio; Elena Verzoni; Sergio Bracarda; Martina Fanelli; Roberto Sabbatini; Rodolfo Passalacqua; Bruno Perrucci; Maria Olga Giganti; Maddalena Donini; Stefano Panni; Marcello Tucci; Veronica Prati; Cinzia Ortega; Anna Caliò; Albino Eccher; Filippo Alongi; Giovanni Pappagallo; Roberto Iacovelli; Alessandra Mosca; Paolo Umari; Ilaria Montagnani; Stefano Gobbo; Francesco Atzori; Enrico Munari; Marco Maruzzo; Umberto Basso; Francesco Pierconti; Carlo Patriarca; Piergiuseppe Colombo; Alberto Lapini; Giario Conti; Roberto Salvioni; Enrico Bollito; Andrea Cossarizza; Francesco Massari; Mimma Rizzo; Renato Franco; Federica Zito-Marino; Yoseba Aberasturi Plata; Francesca Galuppini; Marta Sbaraglia; Matteo Fassan; Angelo Paolo Dei Tos; Maurizio Colecchia; Holger Moch; Maurizio Scaltriti; Camillo Porta; Brett Delahunt; Gianluca Giannarini; Roberto Bortolus; Pasquale Rescigno; Giuseppe Luigi Banna; Alessio Signori; Miguel Angel Llaja Obispo; Roberto Perris; Alessandro Antonelli
Journal:  J Pers Med       Date:  2022-04-30

9.  KCNN4 may weaken anti-tumor immune response via raising Tregs and diminishing resting mast cells in clear cell renal cell carcinoma.

Authors:  Yankang Cui; Tianyi Shen; Feng Xu; Jing Zhang; Yuhao Wang; Jiajin Wu; Hengtao Bu; Dian Fu; Bo Fang; Huichen Lv; Suchun Wang; Changjie Shi; Bianjiang Liu; Haowei He; Hao Tang; Jingping Ge
Journal:  Cancer Cell Int       Date:  2022-06-10       Impact factor: 6.429

10.  Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.

Authors:  Kyohei Watanabe; Takayuki Sugiyama; Atsushi Otsuka; Hideaki Miyake
Journal:  Int Cancer Conf J       Date:  2019-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.